Ypsomed Holding AG (CH:YPSN)
:YPSN
Top Page
Ypsomed Holding AG
(YPSN)
Select Model
Select Model
Rating:70Outperform
Price Target:
CHF304.00
▼(-1.14% Downside)
Action:UpgradedDate:11/13/25
Ypsomed Holding AG's overall stock score is driven by strong financial performance and positive earnings call sentiment, offset by technical analysis indicating potential short-term weakness and a high valuation. Strategic expansions and innovation provide a positive long-term outlook, but cash flow management remains a concern.
Positive Factors
Strong revenue growth & margins
Sustained high revenue growth with healthy gross and net margins indicates durable product demand and effective cost control. Robust margins support reinvestment in R&D and capacity while providing operating leverage that can sustain profitability as volumes scale over the next several quarters.
Negative Factors
Negative free cash flow
Persistently negative free cash flow driven by heavy growth CapEx can stress liquidity and limit flexibility to fund operations or return capital. Unless operating cash conversion improves, the firm may need incremental financing or partner co-investments, creating execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth & margins
Sustained high revenue growth with healthy gross and net margins indicates durable product demand and effective cost control. Robust margins support reinvestment in R&D and capacity while providing operating leverage that can sustain profitability as volumes scale over the next several quarters.
Read all positive factors
Ypsomed Holding AG (YPSN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF3.76B
Dividend Yield0.67%
Average Volume (3M)17.31K
Price to Earnings (P/E)7.7
Beta (1Y)0.48
Revenue Growth27.63%
EPS Growth160.67%
CountryCH
Employees2,600
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)10.19
Shares Outstanding13,649,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)6.82
Price to Sales (P/S)6.19
P/FCF Ratio-35.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.29
Revenue Forecast (FY)CHF703.65M
Ypsomed Holding AG Business Overview & Revenue Model
Company Description
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabete...
How the Company Makes Money
Ypsomed primarily makes money by selling medical-device products and related services in two main areas: (1) Drug Delivery Systems and (2) Diabetes Care. In Drug Delivery Systems, the company generates revenue by developing, industrializing, and m...
Ypsomed Holding AG Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 27, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance and strategic expansions in capacity and innovation. Despite some challenges in specific segments and the impact of phaseouts, the overall outlook remains positive.Positive Updates
Strong Revenue Growth
Ypsomed reported sales of CHF 363 million in the first half year, with the core business growing by 21% from CHF 220 million to CHF 267 million.
Negative Updates
Flat Growth in Pen Segment
The pen business experienced flat growth due to product and customer mix, impacting overall segment performance.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Ypsomed reported sales of CHF 363 million in the first half year, with the core business growing by 21% from CHF 220 million to CHF 267 million.
Read all positive updates
Company Guidance
During the Ypsomed Half Year Results 2025-2026 Earnings Conference call, the company provided several key financial metrics and guidance for the fiscal year. Ypsomed reported first-half sales of CHF 363 million, with the Delivery Systems business contributing CHF 267 million and experiencing a 21% year-over-year growth. The company achieved an EBIT of CHF 152 million, noting a strong 32.4% EBIT margin in the Delivery Systems segment. Ypsomed maintains a robust financial position with an equity ratio of around 67% and a net debt-to-EBITDA ratio of 0.3x. Looking forward, Ypsomed confirmed its guidance for the fiscal year with an expected 20% growth in Delivery Systems sales and an EBIT range of CHF 190 million to CHF 210 million. Midterm ambitions include doubling sales to CHF 900 million to CHF 1.2 billion and achieving an EBIT between CHF 280 million and CHF 340 million, maintaining an EBIT margin above 30%. The company also plans to triple its device capacity to 1 billion units by the end of the decade, supported by CHF 1.5 billion in growth CapEx and customer co-investments.Ypsomed Holding AG Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
75
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 787.55M | 748.87M | 548.46M | 497.46M | 464.84M | 403.66M |
| Gross Profit | 324.84M | 292.07M | 189.05M | 140.59M | 113.82M | 94.83M |
| EBITDA | 275.02M | 190.90M | 161.56M | 137.51M | 96.66M | 65.19M |
| Net Income | 194.00M | 87.50M | 78.37M | 51.27M | 23.11M | 5.81M |
Balance Sheet | ||||||
| Total Assets | 1.21B | 1.33B | 1.10B | 861.88M | 756.91M | 717.68M |
| Cash, Cash Equivalents and Short-Term Investments | 36.30M | 36.49M | 74.02M | 25.22M | 17.04M | 22.41M |
| Total Debt | 110.00M | 267.00M | 256.00M | 157.00M | 267.00M | 215.00M |
| Total Liabilities | 401.49M | 650.66M | 483.66M | 299.55M | 364.37M | 322.30M |
| Stockholders Equity | 807.19M | 679.68M | 617.73M | 562.33M | 392.54M | 395.38M |
Cash Flow | ||||||
| Free Cash Flow | -21.70M | -128.95M | -32.09M | -39.64M | -41.72M | -40.75M |
| Operating Cash Flow | 211.68M | 148.20M | 163.22M | 129.53M | 85.71M | 85.83M |
| Investing Cash Flow | -49.81M | -267.27M | -195.07M | -122.02M | -125.70M | -106.91M |
| Financing Cash Flow | -226.30M | 82.25M | 81.07M | 1.26M | 38.12M | 26.67M |
Ypsomed Holding AG Technical Analysis
Negative
307.50
Price Trends
292.03
Negative
309.05
Negative
345.24
Negative
Market Momentum
-2.52
Positive
40.67
Neutral
15.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:YPSN, the sentiment is Negative. The current price of 307.5 is above the 20-day moving average (MA) of 282.45, above the 50-day MA of 292.03, and below the 200-day MA of 345.24, indicating a bearish trend. The MACD of -2.52 indicates Positive momentum. The RSI at 40.67 is Neutral, neither overbought nor oversold. The STOCH value of 15.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:YPSN.
Ypsomed Holding AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | CHF29.61B | 38.35 | 4.44% | 0.44% | 0.39% | -12.46% | |
70 Outperform | CHF3.76B | 7.66 | 27.15% | 0.67% | 27.63% | 160.67% | |
69 Neutral | CHF2.99B | 34.95 | 23.76% | 0.45% | 16.59% | 65.76% | |
62 Neutral | CHF3.38B | 19.36 | 15.79% | 0.51% | 0.77% | 16.70% | |
61 Neutral | CHF4.53B | 26.89 | ― | 2.36% | 5.84% | 8.57% | |
55 Neutral | CHF1.71B | -14.70 | 4.57% | 2.31% | -9.34% | -37.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CH:YPSN
Ypsomed Holding AG
276.00
-60.72
-18.03%
CH:ALC
Alcon
59.26
-22.23
-27.28%
CH:MOVE
Medacta Group SA
149.60
24.02
19.13%
CH:SFZN
Siegfried Holding AG
75.00
-13.82
-15.56%
CH:TECN
Tecan Group AG
133.40
-26.40
-16.52%
CH:GALE
Galenica AG
90.85
13.68
17.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.